{
    "root": "311ae682-1c49-44e0-e063-6394a90a5184",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "bupropion",
    "value": "20250324",
    "ingredients": [
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        }
    ],
    "indications": "Bupropion hydrochloride extended-release (SR) tablets are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).\n                  The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .\n\n \n                  The efficacy of bupropion hydrochloride extended-release (SR) tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .",
    "contraindications": "Starting dose: 150 mg/day. ( 2.1 ) General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) After 3 days, may increase the dose to 300 mg/day, given as 150 mg twice daily at an interval of at least 8 hours. ( 2.1 ) Usual target dose: 300 mg/day as 150 mg twice daily. ( 2.1 ) Maximum dose: 400 mg/day, given as 200 mg twice daily, for patients not responding to 300 mg/day. ( 2.1 ) Periodically reassess the dose and need for maintenance treatment. ( 2.1 ) Moderate to severe hepatic impairment: 100 mg daily or 150 mg every other day. ( 2.2 , 8.7 ) Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "Bupropion hydrochloride extended-release tablets USP (SR), 100 mg of bupropion hydrochloride, are blue, round, biconvex, film-coated tablets debossed with “S” on one side and “522” on the other.\n                  NDC: 70518-2641-00\n                  NDC: 70518-2641-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with a seizure disorder.\n                     Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate-release formulation of bupropion\n  \n   [see\n   \n    Warnings and Precautions (5.3)]\n  \n   .\n \n  \n                     Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7.3)]\n  \n   .\n \n  \n                     The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release (SR) tablets or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release (SR) tablets is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release (SR) tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release (SR) tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release (SR) tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated\n  \n   [see\n   \n    Dosage and Administration (2.4,\n   \n    2.5),\n  \n   \n                        \n                           Warnings and Precautions (5.4)\n                        \n                        ,\n   \n    Drug Interactions (7.6)].\n  \n   \n                     \n                     Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release (SR) tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported\n  \n   [see\n   \n    Warnings and Precautions (5.8)]\n  \n   ."
}